Daily Stock Analysis, AGEN, Agenus Inc, priceseries

Agenus Inc. Daily Stock Analysis
Stock Information
Open
2.60
Close
2.63
High
2.67
Low
2.53
Previous Close
2.60
Daily Price Gain
0.03
YTD High
3.88
YTD High Date
Jan 18, 2019
YTD Low
2.29
YTD Low Date
Jan 2, 2019
YTD Price Change
0.12
YTD Gain
4.78%
52 Week High
3.88
52 Week High Date
Jan 18, 2019
52 Week Low
1.54
52 Week Low Date
Oct 30, 2018
52 Week Price Change
-0.94
52 Week Gain
-26.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
3.52
Jul 27. 2017
4.77
27 Trading Days
35.64%
Link
LONG
Sep 26. 2017
4.16
Oct 13. 2017
4.54
13 Trading Days
9.02%
Link
LONG
Feb 14. 2018
3.84
Mar 15. 2018
5.53
20 Trading Days
43.92%
Link
LONG
Aug 21. 2018
1.88
Sep 6. 2018
2.03
11 Trading Days
7.87%
Link
LONG
Dec 6. 2018
2.35
Dec 13. 2018
2.50
5 Trading Days
6.56%
Link
LONG
Jan 2. 2019
2.51
Jan 28. 2019
3.43
17 Trading Days
36.54%
Link
Company Information
Stock Symbol
AGEN
Exchange
NasdaqCM
Company URL
http://www.agenusbio.com
Company Phone
781-674-4410
CEO
Garo H. Armen
Headquarters
Massachusetts
Business Address
3 FORBES ROAD, LEXINGTON, MA 02421
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001098972
About

Agenus, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its core technology portfolio consists of Saponin platform and Heat Shock Protein platform. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Description

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.